Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03067272 · ClinicalTrials.gov registry record · NA
Pilot Bi-Lateral Tubal Occlusion Trial for Female Permanent Contraception
A NA study of Contraception, sponsored by Femasys.
- Completed
- Registry status
- NA
- Development phase
- 49
- Enrollment target
- 4
- Study locations
NCT03067272: Completed NA study of Contraception, sponsored by Femasys.
NCT03067272 is a NA study of Contraception that has completed, run by Femasys. The registered enrollment target is 49 participants, below the 454-participant average among 72 other Contraception trials with a reported enrollment target (89% lower). The trial reports 4 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03067272, a NA study of Contraception, has completed, sponsored by Femasys.
- COMPLETED
- Registry status
- NA
- Development phase
- 49 participants
- Enrollment target
- 4
- Study locations
Study Summary
Prospective, multi-center, pilot study evaluating the safety of the FemBloc® Permanent Contraceptive System for female sterilization in preventing pregnancy.
Primary Outcome
Evaluated up to 3 months after the FemBloc treatment procedure
Conditions Studied
Interventions
- DEVICE FemBloc® Permanent Contraceptive System
Study Locations (4)
Florida
- Altus Research Inc. - Lake Worth
New York
- New York Presbyterian Hospital - Columbia University Medical Center - New York
North Carolina
- University of North Carolina, Chapel Hill - Chapel Hill
Tennessee
- Chattanooga Medical Research - Chattanooga
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 49 participants |
| Start Date | 2017-03-15 |
| Est. Completion | 2023-03-14 |
| Phase | NA |
What the finished NCT03067272 record still lists
NCT03067272 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 49 participants, a relatively small participant target, below the 454-participant average among 72 other Contraception trials with a reported enrollment target (89% lower).
The record links to 1 condition, with Contraception appearing as the primary indexed condition, and to 1 intervention - of which FemBloc® Permanent Contraceptive System is the first listed.
NCT03067272 reports a single indexed study location in Florida, New York, North Carolina.
Frequently Asked Questions
What is clinical trial NCT03067272 about?
NCT03067272 is a clinical study titled "Pilot Bi-Lateral Tubal Occlusion Trial for Female Permanent Contraception". Prospective, multi-center, pilot study evaluating the safety of the FemBloc® Permanent Contraceptive System for female sterilization in preventing pregnancy.
What is the current status of trial NCT03067272?
This trial is currently completed. It is a NA study. The enrollment target is 49 participants. The study started on 2017-03-15. Estimated completion is 2023-03-14.
What conditions does trial NCT03067272 study?
This clinical trial studies the following conditions: Contraception.
What interventions are being tested in trial NCT03067272?
The interventions under investigation include: FemBloc® Permanent Contraceptive System (DEVICE).
Who is sponsoring clinical trial NCT03067272?
This trial is sponsored by Femasys, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03067272 being conducted?
This trial has 4 study locations across Florida, New York, North Carolina, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Contraception
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03067272's enrollment target sits among peer trials
49 53rd of 72 higher than 20 of 72 other Contraception trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Contraception trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Patient-clinical Linkages to Improve Trust and Engagement in Postpartum Healthcare
RECRUITING · NA
-
Empathy Through Pain Control: Lidocaine Paracervical Block for IUD Placements
RECRUITING · NA
-
Hormonal Contraception Access Through Pharmacist Prescribing Implementation
RECRUITING · NA
-
Prospective Multi-Center Trial for FemBloc Permanent Birth Control
RECRUITING · NA
-
Contraceptive Efficacy Study of Ovaprene
RECRUITING · NA
-
Intervening on Women's Health for Rural Young Cancer Survivors
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02704858 · 49 participants · Phase 1
Safety and Efficacy Study in Recurrent or Progressive Grade III or IV IDH1 Mutated Glioma
- NCT03516708 · 49 participants · Phase 1
Epacadostat (INCB024360) Added to Preoperative Chemoradiation in Patients With Locally Advanced Rectal Cancer
- NCT03692429 · 49 participants · Phase 1
alloSHRINK - Standard cHemotherapy Regimen and Immunotherapy With Allogeneic NKG2D-based CYAD-101 Chimeric Antigen Receptor T-cells
- NCT04329494 · 49 participants · Phase 1
PIPAC for the Treatment of Peritoneal Carcinomatosis in Patients With Ovarian, Uterine, Appendiceal, Colorectal, or Gastric Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI